IL6 and COVID-19: The targeting of IL-6 on treatment development (not only) in cardiovascular disease and COVID-19 is still under ongoing research, although tocilizumab has been shown to be effective in reducing the pro-atherogenic effects of IL-6, and it has been suggested that it improves patient survival with COVID-19 [40].